Micromet, Inc.: SWOT Analysis & Company Profile by BusinessReview

VIEWS: 21 PAGES: 23

More Info
									Micromet, Inc.

_________________________________________________________________________________




Micromet, Inc.: SWOT Analysis & Company
Profile


Reference code: BRPH151CP10-Q4

Published: Feb 2010




Business Review
John Carpenter House
7 Carmelite Street
London EC4Y 0BS
United Kingdom
Tel: +44 (0) 20 7936 6400
Fax: +44 (0) 20 7336 6813



___________________________________________________________________________________________

Micromet, Inc. - SWOT Profile                                                       Page 1
Micromet, Inc.

__________________________________________________________________________________________


Micromet, Inc. - Company Overview

Micromet, Inc. (Micromet) is a biopharmaceutical company engaged in the development of novel antibody-based drugs
and products for the treatment of cancer, inflammatory, and autoimmune diseases. Its product development pipeline
includes novel antibodies generated with its proprietary BiTE antibody platform and conventional monoclonal antibodies. It
has its research and development facility in Munich, Germany. The company is headquartered in Bethesda, United
States.

In January 2009, the company entered into an agreement with Bayer Schering Pharma AG. Under the terms of
agreement, Micromet granted Bayer Schering Pharma an exclusive option to license a specified BiTE antibody against an
undisclosed solid tumor target. In June 2009, the company's Blinatumomab, a novel therapeutic antibody that activates
patient's T-cells to destroy cancer cells achieved primary endpoint in Phase-II clinical trial. In October 2009, the company
entered into a licensing and co-development agreement with Sanofi-Aventis to develop BiTE antibody against an antigen
related to carcinoma cells. As per the terms of the agreement, the company will be responsible for the discovery, research
and development of the BiTE antibody and for the completion of phase 1 clinical trials while Sanofi-aventis will be
responsible for the further development and worldwide commercialization of the BiTE antibody. In November 2009, the
company entered into an agreement with Lonza Group Ltd, for the development and manufacture of blinatumomab
(MT103). As per the terms of the agreement, Lonza will manufacture blinatumomab for clinical trials and will develop the
commercial scale process and supply blinatumomab for the market.


Financial Performance

The company reported revenues of (U.S. Dollars) USD 27.29 million during the fiscal year ended 2008, an increase of
48.00% over 2007. The operating loss of the company was USD 26.07 million during the fiscal year 2008, a decrease of
3.00% over 2007. The net loss of the company was USD 33.23 million during the fiscal year 2008, a decrease of 65.00%
over 2007.




Micromet, Inc. - Key Facts

Micromet, Inc., Key Facts

                                  6707 Democracy Boulevard,
                                  Bethesda, Maryland (MD),          Ticker Symbol, Stock
Corporate Address:                                                                             MITI (NASDAQ)
                                                                    Exchange
                                  20817, United States


Telephone                         + 1 240 7521420                   No. of Employees           104



Fax                               + 1 760 4319980                   Financial Year End         December



URL                               www.micromet.de                   Revenue (in USD Million)   27.29


                                  Medical Equipment ,
Industry                          Pharmaceuticals and Healthcare


Locations                         Germany, United States

Source: Annual Report, Company Website, Primary and Secondary Research




___________________________________________________________________________________________

Micromet, Inc. - SWOT Profile                                                                                      Page 2
Micromet, Inc.

__________________________________________________________________________________________


Micromet, Inc. - Business Description

Micromet is a provider of novel, proprietary antibody-based products for cancer, inflammatory, and autoimmune diseases.
The company operates through a single reportable business segment namely the discovery and development of antibody-
based drug candidates using proprietary technologies.

The company develops novel drugs for cancer, inflammation and autoimmune diseases using its antibody technology
platforms.Their drugs target and destroy tumor cells in treating cancer. They either trap key signaling molecules or
eliminate subpopulations of immune cells which cause acute and chronic inflammation in case acute and chronic
inflammation diseases.

Micromet has developed various products which are in the stages of clinical trials. The portfolio of the company consists
of differentiated products towards the treatment of cancer, inflammation and autoimmune disease. The drug candidates
are derived from antibodies. The products in the development stage include MT103, a BiTE antibody blinatumoma for
treatment of B cell lymphomas and leukemias , MT110, a BiTE antibody for treatment of solid tumors; MT111, a BiTE
antibody for treatment of human cancers expressing carcino embryonal antigen (CEA); MT293 (TRC093), an anti-
angiogenic humanized monoclonal antibody for treatment of solid tumors; MT203, a human antibody for treatment of
inflammatory diseases; Adecatumumab (MT201), a human antibody for treatment of solid tumors; MT228 (MORAb-028),
a human IgM monoclonal antibody; MCSP BiTE, CAIX BiTE, EGFR BiTE Program, CD33 BiTE Program Research, and
EphA2 BiTE Program.

The Blinatumomab is a BiTE antibody for treatment of B cell lymphomas and leukemias and it is in phase 2 clinical trial.
MT111 is towards solid tumors treatment. The MCSP BiTE program is in the research, lead optimization stage and is
produced towards the treatment of Melanoma. The CAIX BiTE, EGFR BiTE Program, CD33 BiTE Program Research and
EphA2 BiTE Program are in the research, lead optimization and development stages. These products are produced
towards the treatment of renal cancer, adenocarcinoma, myelogenous leukemia and solid tumors.

The other products which are being developed by the company include Adecatumumab (MT201), a recombinant human
monoclonal antibody of the IgG1 subclass, for the treatment of most solid tumors such as prostate, breast, colon, gastric,
ovarian, pancreatic, and lung cancer. MT293 (TRC093) developed by the company is a recombinant humanized IgG1
monoclonal antibody and it is in the phase 1 trial. It is licensed to TRACON Pharmaceuticals, Inc. and is being developed
for the treatment of patients with cancer.

Micromet markets its products through direct distribution and with its marketing partners and distribution agents. The
marketing partners of the company include MedImmune, Merck Serono, Boehringer Ingelheim, TRACON
Pharmaceuticals, Inc., Morphotek, and Nycomed.

The company spent $39.19 million towards its research and development activities during the fiscal year 2008 and when
compared to the previous year it has decrease by 34% which was $29.19 million. Its research and development center is
located in Munich, Germany.

The company classifies its geographical locations into four regions namely Switzerland, United States, Germany and
Others. The Switzerland region accounted for 11.5% of the total revenues of the company for the fiscal year 2008,
followed by United States (29.5%), Germany (57%) and others (1.8%).




___________________________________________________________________________________________

Micromet, Inc. - SWOT Profile                                                                                     Page 3
Micromet, Inc.

__________________________________________________________________________________________


Micromet, Inc. - Major Products and Services

Micromet is a provider of proprietary antibody-based products towards the treatment of cancer, inflammatory and
autoimmune diseases. The company’s key products include the following:

Micromet, Inc. Major Products and Services
Blinatumomab

Adecatumumab

MT293 (TRC093)

MT110

MT111

MT228 (MORAb-028

MT203

MT204
Source: Annual Report, Company Website, Primary and Secondary Research




___________________________________________________________________________________________

Micromet, Inc. - SWOT Profile                                                                                     Page 4
Micromet, Inc.

__________________________________________________________________________________________


Micromet, Inc. - History

Micromet, Inc., History

    Year                Event type                                                  Description


                                                In June 2008, the company and Nycomed initiated formal preclinical safety studies for
   2008      Official Trials/Tests
                                                MT203.


                                                In 2007, the company entered into a agreement with TRACON Pharmaceuticals, Inc.
								
To top